Amendments to the Claims

The listing of claims below is intended to replace all prior listings of the claims:

1. (Original) A method for altering the level of an extracellular matrix (ECM) protein produced by a cell, the method including modulating expression or activity of a cell division auto antigen (CDA).

2. (Original) A method according to claim 1 wherein the ECM protein is selected from the group consisting of collagen, elastin, fibrillin, fibronectin, laminin and proteoglycan.

3. (Original) A method according to claim 1 wherein the ECM protein is fibronectin or collagen IV.

4. (Original) A method according to claim 1 wherein the cell originates from renal tissue or vascular tissue.

5. (Original) A method according to claim 1 wherein the cell is selected from the group consisting of a renal podocyte, a renal proximal tubule cell, a renal collecting duct cell, a foam cell and a macrophage cell.

6. (Original) A method according to claim 1 wherein the CDA comprises an N-terminal proline-rich domain, a central basic domain, and a C-terminal bipartite acidic domain.

7. (Original) A method according to claim 1 wherein the CDA is cell division autoantigen 1 (CDA 1), or a fragment, functional equivalent, analogue, mutant or variant thereof.

8. (Currently amended) A method according to claim 7 wherein the CDA1 is encoded by a nucleotide sequence according to ~~Figure 7~~ SEQ ID NO:1.

9. (Currently amended) A method according to claim 7 wherein the CDA1 has an amino acid sequence according to ~~Figure 8~~ SEQ ID NO:2 or functional equivalent or derivative ~~thereof~~ thereof.

10. (Original) A method for treating or preventing a condition related to synthesis of an ECM protein, the method including modulating the expression and/or activity of a CDA.

11. (Original) A method according to claim 10 wherein the condition is fibrosis.

12. (Original) A method according to claim 11 wherein the fibrosis is due to a burn, a heart attack, treatment with a chemotherapeutic drug, exposure to radiation, or surgery.

13. (Currently amended) A method according to claim 11 wherein the fibrosis is major organ ~~fibrosis~~ fibrosis.

14. (Original) A method according to claim 13 wherein the major organ is selected from the group consisting of kidney, liver, heart and eye.

15. (Original) A method according to claim 13 wherein the major organ fibrosis is due to a condition selected from the group consisting of diabetes, hypertension, viral hepatitis, alcohol abuse, macular degeneration, retinal retinopathy and vitreal retinopathy.

16. (Original) A method according to claim 11 wherein the condition is renal fibrosis as a result of diabetes.

17. (Original) A method according to claim 10 wherein the condition is selected from the group including systemic and local scleroderma, keloids, hypertrophic scars, atherosclerosis and restenosis.

18. (Original) A method according to claim 17 wherein the condition is atherosclerosis.

19. (Original) A method according to claim 10 wherein the condition is aneurysm.

20. (Original) A method according to claim 19 wherein the aneurysm is abdominal aortic aneurysm.

21. (Currently amended) A method according to claim 10 wherein the CDA is ~~CDA1~~ CDA1.

22. (Original) A non-human animal for use in studying disorders of the ECM, the animal having a cell capable of expressing a CDA at an altered level.

23. (Original) A non-human animal according to claim 22 wherein the CDA is CDA1.

24. (Original) A method of screening for an agent capable of modulating ECM synthesis, the method including the steps of

providing an animal or a cell capable of expressing a CDA,

exposing the animal or cell to the agent, and

determining the effect of the agent on the CDA expression and/or activity.

25. (Currently Amended) A method according to claim 24 wherein the CDA is ~~CDA1,~~ CDA1.

26. (Original) An agent identified by the method according to claim 24.

27. (Original) A pharmaceutical composition including an agent according to claim 26.

28. (Original) A method for treating or preventing a condition related to an ECM protein, the method including administering to an animal in need thereof an effective amount of a pharmaceutical composition according to claim 27.

29. (Original) A method of modulating CDA expression and/or activity in a cell, the method including exposing the cell to an agent capable of modulating the expression and/or activity of a factor selected from the group consisting of angiotensin II, TGFß and connective tissue growth factor.

30. (Original) A method according to claim 29 wherein the CDA is CDA1.

31. (Original) A method of diagnosing a condition related to the synthesis of a ECM protein in an animal, the method including

obtaining a biological sample from the animal,

determining the level of CDA in the sample, and

comparing the level of CDA in the sample to a reference value

wherein a positive diagnosis is made if the level of CDA in the sample is statistically significantly higher or lower than the reference value.

32. (Currently amended) A method according to claim 31 wherein the CDA is ~~CDA1~~ CDA1.